These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 15039128)
1. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Emberson J; Whincup P; Morris R; Walker M; Ebrahim S Eur Heart J; 2004 Mar; 25(6):484-91. PubMed ID: 15039128 [TBL] [Abstract][Full Text] [Related]
2. Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China. Qin X; Jackson R; Marshall R; Lee L; Cao W; Zhan S; Hu Y Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):96-101. PubMed ID: 19237999 [TBL] [Abstract][Full Text] [Related]
3. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study. Whitfield MD; Gillett M; Holmes M; Ogden E Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425 [TBL] [Abstract][Full Text] [Related]
4. Combining population health and baseline risk strategy by determining an age cutoff for initiating statins in patients with diabetes: a population-based study. Siyambalapitiya S; Bulugahapitiya U; Sithole J; Song S; Fernando DJ; Idris I Diabetes Care; 2007 Aug; 30(8):2025-9. PubMed ID: 17519429 [TBL] [Abstract][Full Text] [Related]
5. Challenges for the management of hypertension in low-resource settings. Mendis S Ethn Dis; 2003; 13(2 Suppl 2):S67-70. PubMed ID: 13677416 [TBL] [Abstract][Full Text] [Related]
6. The National Action Plan for the Prevention and Control of Non-communicable Diseases and Health Promotion in Pakistan--Cardiovascular diseases. Nishtar S; Faruqui AM; Mattu MA; Mohamud KB; Ahmed A J Pak Med Assoc; 2004 Dec; 54(12 Suppl 3):S14-25. PubMed ID: 15745323 [TBL] [Abstract][Full Text] [Related]
7. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645 [TBL] [Abstract][Full Text] [Related]
8. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record. Rabinowitz I; Tamir A Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507 [TBL] [Abstract][Full Text] [Related]
9. Effect of orlistat on cardiovascular disease risk in obese adults. Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142 [TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS): a factorial, cluster-randomized trial of 2 practical cardiovascular disease prevention strategies developed for rural Andhra Pradesh, India. Chow CK; Joshi R; Gottumukkala AK; Raju K; Raju R; Reddy S; Macmahon S; Neal B Am Heart J; 2009 Sep; 158(3):349-55. PubMed ID: 19699856 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular disease risk factor assessment and management in gout: an analysis using guideline-based electronic clinical decision support. Colvine K; Kerr AJ; McLachlan A; Gow P; Kumar S; Ly J; Wiltshire C; Robinson E; Dalbeth N N Z Med J; 2008 Nov; 121(1285):73-81. PubMed ID: 19079439 [TBL] [Abstract][Full Text] [Related]
12. The impact of prevention on reducing the burden of cardiovascular disease. Kahn R; Robertson RM; Smith R; Eddy D Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of lipid-lowering treatment according to lipid level. Pilote L; Ho V; Lavoie F; Coupal L; Zowall H; Grover SA Can J Cardiol; 2005 Jun; 21(8):681-7. PubMed ID: 16003451 [TBL] [Abstract][Full Text] [Related]
14. Women in Pakistan have a greater burden of clinical cardiovascular risk factors than men. Jafar TH Int J Cardiol; 2006 Jan; 106(3):348-54. PubMed ID: 16337043 [TBL] [Abstract][Full Text] [Related]
15. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease. Hennekens CH; Schneider WR Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698 [TBL] [Abstract][Full Text] [Related]
17. Global preventive policies. Strategies at European and worldwide level. Kotseva K Rev Esp Cardiol; 2008 Sep; 61(9):960-70. PubMed ID: 18775238 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular disease knowledge and risk perception among underserved individuals at increased risk of cardiovascular disease. Homko CJ; Santamore WP; Zamora L; Shirk G; Gaughan J; Cross R; Kashem A; Petersen S; Bove AA J Cardiovasc Nurs; 2008; 23(4):332-7. PubMed ID: 18596496 [TBL] [Abstract][Full Text] [Related]
19. Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. Ruilope LM; Segura J Clin Ther; 2005 Oct; 27(10):1658-68. PubMed ID: 16330303 [TBL] [Abstract][Full Text] [Related]
20. [Prevention of classical risk factors. A public health and health policy task]. Keil U Arzneimittelforschung; 1990 Mar; 40(3A):388-94. PubMed ID: 2185772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]